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ABSTRACT
Pneumococci (n = 1033) isolated in the major
paediatric hospitals of Athens during 2001–2004
from children with invasive infections (n = 186),
non-invasive infections (n = 641) and healthy
carriers (n = 206) were studied. The most preval-
ent serotypes were serotypes 14 (44.6%), 19F
(43.5%) and 6B (22.8%) in invasive, non-invasive
and carriage isolates, respectively. Among inva-
sive isolates, the potential coverage by the seven-
valent conjugate vaccine was 75.3%. Resistance
rates to penicillin, amoxycillin, cefotaxime, eryth-
romycin, co-trimoxazole, clindamycin, tetracyc-
line and chloramphenicol were 44.6%, 2.7%,
1.2%, 43.6%, 43.5%, 12.4%, 34.7% and 5.9%,
respectively. The M-phenotype accounted for
68.0% of the erythromycin-resistant isolates. All
isolates were susceptible to oﬂoxacin.
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Streptococcus pneumoniae is a common cause of
infections in childhood. Recent studies have
documented a worldwide increase in the preval-
ence of isolates resistant to antibiotics [1–3]. In
Greece, the spread of penicillin- and multidrug-
resistant strains has been observed since the early
1990s [4]. Since then, occasional studies have
indicated a continuous increase in the frequency
of antibiotic-resistant pneumococci [5–8]. In the
present study, the serotypes and the antibiotic
susceptibilities of pneumococci isolated in Greece
were studied for a 4-year period in order to clarify
current resistance trends and to provide baseline
data before the commencement of systematic use
of the seven-valent conjugate vaccine in 2004.
Consecutive, non-duplicate pneumococci from
infections in children (aged £14 years) treated at
the three major paediatric hospitals in Athens
(Aghia Soﬁa, Penteli and P. & A. Kyriakou)
during 2001–2004 were studied. Additionally,
nasopharyngeal carriage of pneumococci was
studied in healthy children (aged 3–6 years) in
ten day care centres during January–March 2003.
Exclusion criteria in the carriage study were
antibiotic treatment within the preceding
3 months and the presence of respiratory tract
infection or chronic illness.
Species identiﬁcation was performed using
standard methods. Serogrouping was performed
with the Quellung reaction using pooled and
selected factor antisera (Statens Seruminstitut,
Copenhagen, Denmark). Susceptibility to eryth-
romycin (ERY), clindamycin (CLI), co-trimoxazole
(SXT), tetracycline (TET), chloramphenicol (CHL)
and rifampicin was determined using the disk-
diffusion method [9]. MICs of penicillin (PEN),
amoxycillin (AMX), cefotaxime and oﬂoxacin
(OFX) were determined with Etests (AB Biodisk,
Solna, Sweden). Results were interpreted using
the current CLSI (NCCLS) criteria [9]. S. pneumo-
niae ATCC 49619 was used as a reference strain.
Phenotypic characterisation of macrolide resist-
ance was performed as described previously [10].
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Statistical analysis was performed using the chi-
square test.
In total, 827 S pneumoniae isolates causing
infection were obtained from 448 male (54.2%)
and 379 female (45.8%) patients. Of these, 186
were implicated in invasive pneumococcal
disease (IPD) and were recovered from blood
(n = 161), cerebrospinal ﬂuid (n = 20) or other
clinical specimens (n = 5). The age of IPD patients
ranged from 22 days to 14 years; 103 (55.4%) of
these patients were aged £ 2 years. The remaining
641 isolates were recovered from non-invasive
pneumococcal disease (NIPD), mainly acute otitis
media (n = 438), but also eye (n = 106) and lower
respiratory tract infections (n = 97). In the car-
riage study, 206 isolates of S. pneumoniae were
obtained from 873 children (23.6% carriage rate).
The serotype distribution differed among the
IPD, NIPD and carriage isolates (Table 1). The
most prevalent serotype in IPD was serotype 14
(44.6%), followed by 6B, 9V and 19F, together
accounting for 69.9% of IPD isolates. The poten-
tial coverage by the seven-valent conjugate vac-
cine was 75.3%. Nevertheless, vaccine serotypes
were encountered more often among IPD isolates
from patients aged £ 2 years than from older
children (87.4% vs. 60.2%; p < 0.001). The most
frequent serotype in the NIPD group was sero-
type 19F (43.5%), with an additional 32.1% of the
NIPD isolates belonging to serotypes 14, 23F, 6B
and 9V. Among carriage isolates, 6B was the
predominant serotype (22.8%), with another
55.3% of isolates belonging to serotypes 19F, 14,
23F and 9V.
Antibiotic resistance rates were higher among
the NIPD and carriage isolates compared with the
IPD isolates (Table 2). Among IPD isolates, 17.2%
were non-susceptible to PEN, compared with
53% of NIPD isolates and 43.2% of carriage
isolates (p < 0.001). Only 0.5% of IPD isolates
were fully resistant to PEN, while the respective
rates for NIPD and carriage isolates were signi-
ﬁcantly greater (Table 2). Additionally, isolates
with decreased susceptibility to AMX, while
absent in IPD, occurred sporadically among the
NIPD and carriage groups.
Signiﬁcant rates of resistance to ERY were
observed in all three groups, with a resistance
rate of 49.8% among NIPD isolates. The M
phenotype was predominant among the ERY-
resistant pneumococci. Relatively high resistance
rates were found for SXT and TET. All isolates
were susceptible to OFX. Resistance to three or
more drugs (multiresistance) was common
among the NIPD and carriage groups (44.0%
and 36.8%, respectively; Table 2) and was ob-
served more often among IPD isolates from
younger children (£ 2 years; 71.4%).Table 1. Serogroup-serotype distribution of 1033 pneu-
mococcal isolates from various clinical samples
Serotype ⁄
serogroup
Number of isolates (%) obtained from:
Total
n = 1033
IPD
n = 186
NIPD
n = 641
Carriers
n = 206
1 5 (2.7) 7 (1.1) 1 (0.5) 13 (1.3)
2 – 1 (0.2) 1 (0.5) 2 (0.2)
3 1 (0.5) 22 (3.4) 5 (2.4) 28 (2.7)
4 2 (1.1) 2 (0.3) 1 (0.5) 5 (0.5)
6B 21 (11.3) 45 (7.0) 47 (22.8) 123 (11.9)
6-non-B 5 (2.7) 20 (3.1) 4 (1.9) 29 (2.8)
7F 5 (2.7) 3 (0.5) 1 (0.5) 9 (0.9)
8 – 3 (0.5) 2 (1.0) 5 (0.5)
9 V 14 (7.5) 39 (6.1) 26 (12.6) 79 (7.6)
9-non-V 1 (0.5) 2 (0.3) – 3 (0.3)
10 – 6 (0.9) – 6 (0.6)
11 – 11 (1.7) 5 (2.4) 16 (1.5)
12 1 (0.5) 1 (0.2) – 2 (0.2)
14 83 (44.6) 66 (10.3) 21 (10.2) 170 (16.4)
15 1 (0.5) 4 (0.6) 4 (1.9) 9 (0.9)
17 – 1 (0.2) – 1 (0.1)
18C 3 (1.6) 15 (2.3) 2 (1.0) 20 (1.9)
18-non-C 4 (2.2) 3 (0.5) 2 (1.0) 9 (0.9)
19F 12 (6.5) 279 (43.5) 37 (18.0) 328 (31.7)
19-non-F 10 (5.4) 23 (3.6) 2 (1.0) 35 (3.4)
20 1 (0.5) 2 (0.3) 1 (0.5) 4 (0.4)
22 – – 1 (0.5) 1 (0.1)
23F 5 (2.7) 56 (8.7) 30 (14.6) 91 (8.8)
23-non-F 4 (2.2) 3 (0.5) 1 (0.5) 8 (0.8)
33 1 (0.5) – 1 (0.5) 2 (0.2)
Non-typable 7 (3.8) 27 (4.2) 11 (5.3) 45 (4.3)
IPD, invasive pneumococcal disease; NIPD, non-invasive pneumococcal disease.
Table 2. Antibiotic resistance rates of 1033 pneumococcal
isolates from various clinical samples
Antibiotic
Number (%) of non-susceptible isolates
derived from:
Total n = 1033IPD n = 186 NIPD n = 641 Carriers n = 206
Penicillina 32 (17.2) 340 (53.0) 89 (43.2) 461 (44.6)
I 31 (16.6) 234 (36.5) 63 (30.6) 328 (31.8)
R 1 (0.5) 106 (16.5) 26 (12.6) 133 (12.9)
Amoxycillina 0 22 (3.4) 6 (2.9) 28 (2.7)
I 0 22 (3.4) 6 (2.9) 28 (2.7)
Cefotaximea 2 (1.1) 9 (1.4) 1 (0.5) 12 (1.2)
I 2 (1.1) 8 (1.2) 0 10 (1.0)
R 0 1 (0.2) 1 (0.5) 2 (0.2)
Erythromycin 56 (30.1) 319 (49.8) 75 (36.4) 450 (43.6)
M 48 (25.8) 225 (35.1) 33 (16.0) 306 (29.6)
CR 6 (3.2) 87 (13.6) 35 (17.0) 128 (12.4)
IR 2 (1.1) 7 (1.1) 7 (3.4) 16 (1.5)
Co-trimoxazole 44 (23.7) 314 (49.0) 91 (44.2) 449 (43.5)
Chloramphenicol 3 (1.6) 36 (5.6) 22 (10.6) 61 (5.9)
Tetracycline 19 (10.2) 267 (41.7) 72 (35.0) 358 (34.7)
Clindamycin 6 (3.2) 87 (13.6) 35 (17.0) 128 (12.4)
Rifampicin 0 2 (0.3) 0 2 (0.2)
Multiresistantb 21 (11.3) 282 (44.0) 75 (36.8) 378 (36.6)
IPD, invasive pneumococcal disease; NIPD, non-invasive pneumococcal disease; I,
intermediately-susceptible isolates; R, resistant isolates; M, M-phenotype macrolide
resistance; CR, constitutive macrolide resistance; IR, inducible macrolide resistance.
aSum of non-susceptible isolates.
bResistance to three or more drug classes.
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There were evident associations between resist-
ance phenotypes and serotypes. The most fre-
quent multiresistant pattern (PEN, ERY, SXT,
TET) was encountered frequently among serotype
19F isolates (49.4%), followed by the PEN, ERY,
TET pattern (7.6%). The ERY and PEN, ERY, SXT,
CLI patterns were common among serotype 14
isolates (35.3 and 5.9%, respectively). Notably, all
serotype 14 isolates associated with IPD were
monoresistant to ERY. The majority of serotype
9V isolates (54.4%) exhibited the phenotype PEN,
SXT; an additional 6.3% of 9V isolates were
non-susceptible only to PEN. Among 23F isolates,
the commonest resistance patterns were PEN,
ERY, SXT, TET, CLI, CHL and PEN, SXT (14%
and 10%, respectively).
The institutions participating in this study
serve the Athens area, as well as central Greece
and the Aegean islands, thus representing c. 50%
of the total paediatric population in Greece.
Therefore, the sample can be considered to be
representative of the situation in this country. The
serotypes found among IPD isolates, mostly
serotype 14, and more rarely serotypes 1, 3, 4
and 18C, differed from those reported recently in
other European countries [11–14], but the poten-
tial coverage by the seven-valent conjugate
vaccine was as high as in most other studies
conducted in Europe and the USA [11–13].
An important ﬁnding was the high prevalence
of non-susceptibility to common antibiotics
among NIPD isolates. Most of these isolates were
either from acute otitis media following tympano-
centisis (usually performed after treatment fail-
ure), or were from respiratory infections requiring
hospitalisation. It is therefore possible that the
NIPD isolates were partly selected, which might
also explain the differences in serotypes between
NIPD and carriage groups. Indeed, multiresistant
isolates of serotype 19F, though prevalent among
NIPD isolates, accounted for a minor fraction of
pneumococci from carriers. Nevertheless, the
high rates of antibiotic resistance observed in the
latter group demonstrated the spread of multire-
sistant pneumococci in the community, although
it should be noted that other antibiotics, including
AMX, remained highly active against the PEN
non-susceptible pneumococci.
PEN non-susceptibility was less frequent
(17.2%) among IPD isolates, and was lower than
the rates reported in other Mediterranean coun-
tries except Italy [13–16]. In contrast, the high rate
of resistance to ERY in all three groups of isolates
is in line with the globally increasing trend of
macrolide resistance in pneumococci [10,11,13,16–
18]. The dominance of the M resistance phenotype
observed in this study reﬂects the recent increase
of this phenotype in Europe, caused by the spread
of the ST9 clone of serotype 14 [19,20].
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ABSTRACT
The prevalence of antibodies to Rickettsiae and
other tick-borne microrganisms in the sera of 181
forestry rangers from Friuli-Venezia-Giulia, Italy,
was examined. Seven (3.9%) sera were positive for
Rickettsia conorii and Rickettsia helvetica, as single
or dual infections; four of these sera had been
found previously to be positive for Borrelia burg-
dorferi. Antibodies to Coxiella burnetii were detec-
ted in ﬁve (2.8%) sera, four of which were also
positive for B. burgdorferi. These ﬁndings indicate
that patients in this north-eastern Italian region
with fever subsequent to tick-bite should be
investigated for Rickettsia and Coxiella infections.
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Tick-borne diseases caused by organisms trans-
mitted by the tick Ixodes ricinus, such as Lyme
borreliosis (LB), tick-borne encephalitis (TBE) and
anaplasmosis (formerly ehrlichiosis), have been
detected previously in the Friuli-Venezia-Giulia
(FVG) region of Italy [1–3]. Ixodes spp. ticks have
the potential to transmit several human patho-
gens, including members of the rickettsiales.
Patients with antibodies to Rickettsia helvetica,
and evidence of this microrganism in the ticks,
have been reported in Switzerland, Sweden,
France, Portugal and Japan [4], and also in an
Italian region bordering FVG [5–7]. Infections
concomitant with or consecutive to infections
with Coxiella burnetii and other tick-borne organ-
isms, such as Rickettsia conorii, Rickettsia slovaca,
Rickettsia africae and Francisella tularensis, have
been detected in patients from southern France,
none of whom had a history of Q fever [8]. In a
previous prevalence study carried out among 181
forestry rangers from FVG, Italy, seropositivity
levels of 0.6% for TBE virus, 23.2% for Borrelia
burgdorferi and 0.6% for Anaplasma phagocytophi-
lumwere detected, with 21 of the rangers having a
previous diagnosis of LB [1]. The present study
aimed to extend the previous serosurvey by
investigating the presence of antibodies to Rick-
ettsiae and other tick-borne microorganisms in
the same set of sera, obtained from 181 forestry
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